Contact information
My research background is in haematopoiesis and macrophage-lineage cell biology.
My current research focuses on mechanisms of autoimmune disease chronicity and resolution, and identifying biomarkers that predict a response to TNF blockade in RA patients.
Felix Clanchy
PhD, LLB
Postdoctoral Researcher
- GMO Safety Committee
Key publications
-
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.
Journal article
Borghese F. and Clanchy FIL., (2011), Expert Opin Ther Targets, 15, 237 - 251
-
High-Affinity Fc Receptor Expression Indicates Relative Immaturity in Human Monocytes.
Journal article
Clanchy FIL., (2016), J Interferon Cytokine Res, 36, 279 - 290
-
Ibudilast inhibits chemokine expression in rheumatoid synovial fibroblasts and exhibits immunomodulatory activity in experimental arthritis.
Journal article
Clanchy FIL. and Williams RO., (2018), Arthritis Rheumatol
-
Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF+ T Lymphocytes.
Journal article
Bystrom J. et al, (2017), Clin Rev Allergy Immunol, 53, 265 - 276
-
Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy?
Journal article
Aungier SR. et al, (2019), Ann Rheum Dis, 78, 186 - 191
-
The development of macrophages from human CD34+ haematopoietic stem cells in serum-free cultures is optimized by IL-3 and SCF.
Journal article
Clanchy FIL. and Hamilton JA., (2013), Cytokine, 61, 33 - 37
Recent publications
-
Response to: 'Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis' by Cutolo et al.
Journal article
Aungier S. et al, (2019), Ann Rheum Dis
-
Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy?
Journal article
Aungier SR. et al, (2019), Ann Rheum Dis, 78, 186 - 191